Cyclin D as a therapeutic target in cancer
The DOI matches its Crossref record; 191 of the 191 references it cites were found in a registry or an index.
Abstract
Cyclin D1, and to a lesser extent the other D-type cyclins, is frequently deregulated in cancer and is a biomarker of cancer phenotype and disease progression. The ability of these cyclins to activate the cyclin-dependent kinases (CDKs) CDK4 and CDK6 is the most extensively documented mechanism for their oncogenic actions and provides an attractive therapeutic target. Is this an effective means of targeting the cyclin D oncogenes, and how might the patient subgroups that are most likely to benefit be identified?
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Failure to modify cyclin D1 on T286 leads to aberrant nuclear accumulation of the protein, premature S phase entry, and enhanced cellular proliferation that drives tumorigenesis (17).”
From A genome-wide screen reveals that Dyrk1A kinase promotes nucleotide excision repair by preventing aberrant overexpression of cyclin D1 and p21 (2023) · cites this paper as [17]
In the citing paper
“Possibly, CCND1 amplification and CDKN2A loss may contribute to determining response to letrozole alone”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [68]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“The deregulation of cyclin expression or CDK activation can directly lead to some of the hallmarks of cance”
BackgroundComprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115 · cited 1×
“A second well-described non-catalytic role of cyclin D is the sequestration of p21 and p27 by cyclin D–CDK4/CDK6, leading to the indirect activation of CDK2 (REF”
BackgroundIn Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · cited 1×
“It may also be possible to identify low-molecular-mass inhibitors of cyclin–CDK substrate interactions using high-throughput screens that are similar to those used for the discovery and preclinical testing of inhibitors of MDM2–p53 binding (nutlins”
MethodThe landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957 · cited 1×
“by causing proliferation that is independent of normal extracellular cues, or by over-riding checkpoints that ensure genomic integrity and stabilit”
BackgroundFinn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Tyrosine Kinases as Targets for Cancer Therapy
Krause, D. S., & Van Etten, R. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044389 · Cited by 1,387 · cited 1×
“Given the increasingly routine clinical use of specific kinase inhibitor”
BackgroundmTOR and cancer: insights into a complex relationship
Sabatini, D. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1974 · Cited by 1,322 · cited 1×
“In Phase II clinical trials mTOR inhibitors were particularly effective in MCL, which is characterized by almost universal overexpression of cyclin D1, although this may not be accompanied by a reduction in cyclin D1 expression (reviewed in REF”
BackgroundBiological determinants of endocrine resistance in breast cancer
Musgrove, E. A., & Sutherland, R. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2713 · Cited by 1,252
Self-citation
Cited by
Items 601–700 of 1,000
Novotný, J., Bandúrová, V., Strnad, H., Chovanec, M., Hradilová, M., Šáchová, J., Šteffl, M., Grušanović, J., Kodet, R., Pačes, V., et al. (2020) · Cancers · doi:10.3390/cancers12040792 · Cited by 26
“These results are in agreement with the current opinion that tumors can be addicted to cyclin D-dependent CDK4/6 kinase activity [56] and that CDK4/6–cyclin D complexes represent promising targets in cancer therapy [18,20,41].”
BackgroundResultInfluentialThe hallmarks of ovarian cancer: proliferation and cell growth
López-Reig, R., & López-Guerrero, J. A. (2020) · European Journal of Cancer Supplements · doi:10.1016/j.ejcsup.2019.12.001 · Cited by 28
“[7] Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL.”
BackgroundAnalysis of tripartite motif (TRIM) family gene expression in prostate cancer bone metastases
Offermann, A., Kang, D., Watermann, C., Weingart, A., Hupe, M. C., Saraji, A. A., Stegmann-Frehse, J., Kruper, R., Schüle, R., Pantel, K., et al. (2021) · Carcinogenesis · doi:10.1093/carcin/bgab083 · Cited by 24
Hou, M., Li, H., He, T., Hui, S., Dai, W., Hou, X., Zhao, J., Zhao, J., Wen, J., Kan, W., et al. (2023) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgad103 · Cited by 24
“Studies support the use of Cyclin D1 expression as a survival indicator for breast cancer patients [32].”
ResultChae, J., Jeon, Y., & Shim, J. (2014) · Phytotherapy Research · doi:10.1002/ptr.5217 · Cited by 24
“Abnormally high levels of cyclin D1 are associated with tumorigenesis in human cancers (Albanese et al., 1995; Weinstein, 1996; Musgrove et al., 2011).”
BackgroundCyclin D1 promotes BRCA2-Rad51 interaction by restricting cyclin A/B-dependent BRCA2 phosphorylation
Chalermrujinanant, C., Michowski, W., Sittithumcharee, G., Esashi, F., & Jirawatnotai, S. (2015) · Oncogene · doi:10.1038/onc.2015.354 · Cited by 25
Magro, G. G., Salvatorelli, L., Alaggio, R., D’Agata, V., Nicoletti, F., Cataldo, A. D., & Parenti, R. (2016) · Human Pathology · doi:10.1016/j.humpath.2016.07.038 · Cited by 24
Or, C.-H. R., Chang, Y., Lin, W.-C., Lee, W.-C., Su, H., Cheung, M.-W., Huang, C.-P., Ho, C., & Chang, C. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms18010044 · Cited by 25
“Importantly, cyclin D1 overex ression lea s to uncontrolle cell proliferation and is linked to the development, progression, poor prognosis, an che oresistance of a broa range of h an alignancies, incl ing colorectal cancer, thus aking cyclin 1 a potential therapeutic target [27,28].”
BackgroundPAQR4 has a tumorigenic effect in human breast cancers in association with reduced CDK4 degradation
Zhang, H., Han, R., Ling, Z., Zhang, F., Hou, Y., You, X., Huang, M., Zhao, Z., Wang, Z., & Chen, Y. (2017) · Carcinogenesis · doi:10.1093/carcin/bgx143 · Cited by 25
“The expression of cyclin D1 and activation of CDK4 and CDK6 can drive proliferation of breast cancer cells (10,11).”
BackgroundEpstein-Barr Virus Nuclear Antigen 3C Facilitates Cell Proliferation by Regulating Cyclin D2
Pei, Y., Singh, R. K., Shukla, S. K., Lang, F., Zhang, S., & Robertson, E. S. (2018) · Journal of Virology · doi:10.1128/jvi.00663-18 · Cited by 24
“As critical components of cell cycle progression, cyclin D family members are typically dysregulated in cancers, which makes them valuable therapeutic targets for cancer therapy (13).”
BackgroundInfluentialRN181 is a tumour suppressor in gastric cancer by regulation of the ERK/MAPK–cyclin D1/CDK4 pathway
Wang, S., Wang, X., Gao, Y., Yingxia, P., Dong, N., Xie, Q. R., Zhang, X., Wu, Y., Li, M., & Li, J. (2019) · The Journal of Pathology · doi:10.1002/path.5246 · Cited by 25
“Indeed, up-regulation of cyclin D1 and CDK4 was observed in a wide spectrum of tumours [22,24,26].”
Gristina, V., Mantia, M. L., Galvano, A., Cutaia, S., Barraco, N., Castiglia, M., Perez, A., Bono, M., Iacono, F., Greco, M., et al. (2021) · Journal of Molecular Pathology · doi:10.3390/jmp2020016 · Cited by 24
“In fact, NGS allows to examine both DNA- and RNA-based aberrations, thus concurrently analyzing significant gene pathogenic variants [12–14].”
BackgroundInfluentialConsequence of the tumor-associated conversion to cyclin D1b
Augello, M. A., Berman‐Booty, L. D., Carr, R., Yoshida, A., Dean, J. L., Schiewer, M. J., Feng, F. Y., Tomlins, S. A., Gao, E., Koch, W. J., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404242 · Cited by 23
“The most well-described function of cyclin D1 outside cell cycle control is the ability to act as a transcriptional co-regulator (Bienvenu et al, 2010; Musgrove et al, 2011).”
BackgroundInfluentialGao, L., & Wang, G. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s171705 · Cited by 25
“28 Activation of CCNB1 was found to promote cell proliferation and tumor growth in colorectal cancer cells.”
Guo, X., Zhu, F., Pan, L., Chen, J., Lai, J., Wu, H., & Shu, J. (2020) · Oncology Letters · doi:10.3892/ol.2020.11712 · Cited by 25
“These proteins are frequently deregulated in cancer and are biomarkers of cancer phenotype and disease progression (27).”
BackgroundTanaka, Y., Murata, M., Tanegashima, K., Oda, Y., & Ito, T. (2022) · Scientific Reports · doi:10.1038/s41598-022-07727-x · Cited by 23
Liu, J., Lin, J., Wang, X., Zheng, X., Gao, X., Huang, Y., Chen, G., Xiong, J., Lan, B., Chen, C., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.725679 · Cited by 31
“Accumulating evidence shows that CCND1 amplification is a possible risk factor for many cancers (31, 32).”
BackgroundKrasniqi, E., Goeman, F., Pulito, C., Palcau, A. C., Ciuffreda, L., Lisa, F. S. D., Filomeno, L., Barba, M., Pizzuti, L., Cappuzzo, F., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314534 · Cited by 23
Green, A. K., Zhou, Q. C., Iasonos, A. E., Zammarrelli, W. A., Weigelt, B., Ellenson, L. H., Chhetri-Long, R., Shah, P., Loh, J., Hom, V., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1999 · Cited by 31
Zhang, F., Wang, Z., Yuan, J., Wei, X., Tian, R., & Niu, R. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3529-6 · Cited by 24
“expression of cyclin D1 frequently occurs in human breast cancer and is correlated with disease aggravation [30, 46].”
Qu, J., Song, M. S., Xie, J., Huang, X., Hu, X., Gan, R.-H., Zhao, Y., Lin, L., Chen, J., Lin, X., et al. (2015) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-015-2575-z · Cited by 23
“cancer onset and tumor progression and many types of cancer [31].”
BackgroundSPAG9 is overexpressed in human prostate cancer and promotes cancer cell proliferation
Li, H., Yang, P., Niu, H., Wu, B., Zhang, Y., Zhang, Y., Bai, X., & He, P. (2014) · Tumor Biology · doi:10.1007/s13277-014-1947-4 · Cited by 23
Lucas, T. F. G., Amaral, L. S., Porto, C. S., & Quintas, L. E. M. (2012) · Reproduction · doi:10.1530/rep-12-0232 · Cited by 23
Cyclin D1 G870A polymorphism and lung cancer risk: a meta-analysis
Liu, J., Liao, Q., Zhang, Y., Sun, S., Zhong, C., & Liu, X. (2012) · Tumor Biology · doi:10.1007/s13277-012-0397-0 · Cited by 23
“Besides, CCND1 G870A polymorphism may be used as a good biomarker of lung cancer phenotype and disease progression in the future [45].”
BackgroundMa, Z., Ma, Y., Xia, Q., Li, Y., Li, R., Chang, W., Chen, J., Leng, Z., & Tao, K. (2016) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-016-2139-y · Cited by 23
“In fact, upregulated cyclin D1 has been detected in a series of human malignancies to date, including GC (Kishimoto et al. 2008; Musgrove et al. 2011).”
BackgroundChen, M., Zhong, L., Yao, S., Zhao, Y. C., Liu, L., Li, L., Xu, T., Gan, L., Xiao, C., Shan, Z., et al. (2017) · International Journal of Medical Sciences · doi:10.7150/ijms.19682 · Cited by 24
“cyclinD1, which is closely involved in the proliferation of cancer cells, plays an important role in the G1/S phase transition, which may facilitate the occurrence of tumors [30].”
BackgroundMaharjan, S., Park, B. K., Lee, S. I., Lim, Y., Lee, K., & Kwon, H. (2018) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2017.235 · Cited by 24
“Cyclin D1 is a vital mediator of cell cycle progression from the G1 to the S phase in response to stimulation by growth factors (Musgrove et al., 2011; Casimiro et al., 2012; Qie and Diehl, 2016).”
BackgroundHsa‑miR‑376c‑3p targets Cyclin D1 and induces G1‑cell cycle arrest in neuroblastoma cells
Bhavsar, S. P., L�kke, C., Fl�gstad, T., & Einvik, C. (2018) · Oncology Letters · doi:10.3892/ol.2018.9431 · Cited by 23
“These cyclins through the phosphorylation of the substrates at specific cell stages co-ordinates the sequential completion of DNA replication and cell division (23).”
InfluentialCui, D., Qian, R., & Li, Y. (2019) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.999 · Cited by 23
Brązert, M., Kranc, W., Nawrocki, M. J., Sujka‐Kordowska, P., Konwerska, A., Jankowski, M., Kocherova, I., Celichowski, P., Ješeta, M., Ożegowska, K., et al. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.10963 · Cited by 24
Protective role of anticancer drugs in neurodegenerative disorders: A drug repurposing approach
Advani, D., Gupta, R. V., Tripathi, R. S., Sharma, S., Ambasta, R. K., & Kumar, P. (2020) · Neurochemistry International · doi:10.1016/j.neuint.2020.104841 · Cited by 25
Chen, Y., Zhang, Q., Wang, Q., Li, J., Sipeky, C., Xia, J., Gao, P. H., Hu, Y., Zhang, H., Yang, X., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-04731-4 · Cited by 23
Roles of Cx43 and AKAP95 in ovarian cancer tissues in G1/S phase.
Liu, W., Hua, S., Dai, Y., Yuan, Y., Yang, J., Deng, J., Huo, Y., Chen, X., Teng, B., Yu, X., et al. (2015) · PubMed Central · Cited by 22
Su, C., Liu, S., Ma, X., Liu, J., Liu, J., Lei, M., & Cao, Y. (2021) · Cell Biology International · doi:10.1002/cbin.11684 · Cited by 22
Prével, C., Kurzawa, L., Van, T. N. N., & Morris, M. C. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.10.003 · Cited by 23
Tspan5 is an independent favourable prognostic factor and suppresses tumour growth in gastric cancer
He, P., Wang, S., Zhang, X., Gao, Y., Niu, W., Dong, N., Shi, X., Geng, Y., Ma, Q., Li, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9514 · Cited by 22
“Therefore, CDKI, cyclin D1, CDK4, pRB and E2F encompass the central players in the cell cycle transition from G1-S phase [25, 28, 29].”
BackgroundSong, H. M., Park, G. H., Park, S. B., Kim, H., Son, H.-J., Um, Y., & Jeong, J. B. (2018) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x18500118 · Cited by 22
Gao, F., Li, M., Zhou, L. Q., Liu, W., Zuo, H., & Li, W. (2020) · Oncology Reports · doi:10.3892/or.2020.7697 · Cited by 22
Hu, Y., Li, S., Liu, F., Geng, L., Shu, X. H., & Zhang, J. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.08.050 · Cited by 24
da Silva, G. N., de Camargo, E. A., & Salvadori, D. M. F. (2012) · Molecular Biology Reports · doi:10.1007/s11033-012-1916-1 · Cited by 22
“The upregulation of CDK6, CDK8 and BIRC5 have already been associated with cancer [44, 45].”
BackgroundDoğan, S., & Şimşek, T. (2016) · Medical Hypotheses · doi:10.1016/j.mehy.2016.04.041 · Cited by 22
Tan, W., Guan, H., Zou, L.-H., Wang, Y., Liu, X., Rang, W., Zhou, P., Pei, H., & Zhong, C. (2017) · Cancer Medicine · doi:10.1002/cam4.995 · Cited by 22
“Many cell regulators and DNA damage response players, such as cyclinD1 [29, 30], PLK1 [31, 32] and BRCA1 [20, 33], are mutated or dysregulated in cancers.”
BackgroundAbroudi, A. S., Samarasinghe, S., & Kulasiri, D. (2017) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2017.06.018 · Cited by 25
“Although Cdk4 is abundant during cell cycle, it needs to bind to Cyclin D to become functional toward its targets (Musgrove et al., 2011).”
BackgroundLamy, S., Muhire, É., & Annabi, B. (2017) · Journal of Functional Foods · doi:10.1016/j.jff.2017.10.048 · Cited by 23
Wang, S., Wang, L., Sun, D., Chai, C., Hsi, E., Kuo, H., Yokoyama, K. K., & Hsu, S. (2016) · Oncotarget · doi:10.18632/oncotarget.9228 · Cited by 21
“Given that ISX transactivates cyclin D1 and the E2F1 promoter (Figure 2A, 2B, and 2D), highly expressed cyclin D1 might also affect the expression of nuclear RB1, DP1, E2F1, and p-E2F1 via control of chromosomal stability [33] or of phosphorylation of E2F1, RB or DP1 via cdk4 / cdk6 kinases [34].”
BackgroundNoninvasive PET Imaging of CDK4/6 Activation in Breast Cancer
Ramos, N. N., Baquero‐Buitrago, J., Youss, Z. B., Wadghiri, Y. Z., Reiner, T., Boada, F. E., & Carlucci, G. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.232603 · Cited by 21
“Subsequent to cell damage, the cyclin D1 (cycD1)–CDK4/6 complex arrests the cell cycle progression in G1 to limit the proliferation of the DNA-damaged cells (13).”
BackgroundYu, W., Zhang, X., Zhang, W., Xiong, M., Lin, Y.-H., Chang, M., Xu, L., Lü, Y., Liu, Y., & Zhang, J. (2021) · Experimental Hematology and Oncology · doi:10.1186/s40164-021-00243-0 · Cited by 24
Zhang, X., Wang, Y., Zhang, X., Shen, Y., Yang, K., Ma, Q., Qiao, Y., Shi, J., Wang, Y., Xu, L., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01359-x · Cited by 23
“(CDKs) including CDK4 and CDK6 and executes its oncogenic effect by promoting unlimited cell cycle progression.(27) We thus selected three sensitive ESCC cell lines with CCND1 copy number >2 and three resistant ESCC cell lines with CCND1 copy number <2 to interrogate cell cycle pathway focusing on G1 phase regulation.”
BackgroundTargeting Oral Cancer: In Silico Docking Studies of Phytochemicals on Oncogenic Molecular Markers
Priyadarshini, G., Gheena, S., Dilipan, E., & Ramani, P. (2024) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2024.25.6.2069 · Cited by 21
“The most well-established mechanism for these cyclin’s carcinogenic effects is their activation of the cyclin-dependent kinases (CDKs) CDK4 and CDK6, which makes them a desirable target for therapy [16].”
BackgroundShimura, T., Hamada, N., Sasatani, M., Kamiya, K., & Kunugita, N. (2014) · Cell Cycle · doi:10.4161/cc.28139 · Cited by 21
“Cyclin D1 is considered a potential therapeutic target for treating cancer.(29,30) Our results reveal that cyclin D1 is also a marker of long-term exposure to low-dose radiation in human cells.”
BackgroundDai, X., Zeng, X., Peng, F., Han, Y., Lin, H., Xu, Y., Zhou, T., ., G. X., Deng, Y., Mao, Y.-Q., et al. (2012) · Cellular Physiology and Biochemistry · doi:10.1159/000337609 · Cited by 21
Andrew, A. S., Hu, T., Gu, J. H., Gui, J., Ye, Y., Marsit, C. J., Kelsey, K. T., Schned, A. R., Tanyos, S. A., Pendleton, E. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051301 · Cited by 21
“For example, cell proliferation is controlled by proteins that maintain the synchrony of cell growth, DNA synthesis, mitosis, and cell division [5,6].”
Zhang, J., Ouyang, W., Li, J., Zhang, D., Yu, Y., Wang, Y., Li, X., & Huang, C. (2012) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2012.06.012 · Cited by 21
“Cyclin D1 overexpression has been observed in many human cancer tissues, including breast cancer, lung cancer, pancreatic cancer, and non-melanoma skin cancer, particularly in keratoacanthomas and squamous cell carcinomas (SCCs) (Musgrove et al., 2011).”
InfluentialMisexpression of cyclin D1 in embryonic germ cells promotes testicular teratoma initiation
Lanza, D. G., Dawson, E. P., Rao, P., & Heaney, J. D. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1149272 · Cited by 23
Identification of new candidate therapeutic target genes in head and neck squamous cell carcinomas
Sablin, M., Dubot, C., Klijanienko, J., Vacher, S., Ouafi, L., Chemlali, W., Caly, M., Sastre‐Garau, X., Lappartient, E., Mariani, O., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10163 · Cited by 21
“We also analyzed MKI67 and CCND1 mRNA levels as prognostic controls [23].”
MethodLu, Z., Huang, F., Cao, R. Y., Tan, G., Yi, G., He, N., Xu, L., & Zhang, L. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b07801 · Cited by 21
GATA1 Promotes Gemcitabine Resistance in Pancreatic Cancer through Antiapoptotic Pathway
Chang, Z., Zhang, Y., Liu, J., Guan, C., Gu, X., Yang, Z., Ye, Q., Ding, L., & Liu, R. (2019) · Journal of Oncology · doi:10.1155/2019/9474273 · Cited by 21
“Mechanistically, cyclin D2, frequently thought to play a critical role in promoting tumor cell proliferation [34], was upregulated in GATA1 overexpressed cells.”
BackgroundStathmin 1 Induces Murine Hepatocyte Proliferation and Increased Liver Mass
Zhao, E., Shen, Y., Amir, M., Farris, A. B., & Czaja, M. J. (2019) · Hepatology Communications · doi:10.1002/hep4.1447 · Cited by 24
Cisse, O., Quraishi, M., Gulluni, F., Guffanti, F., Mavrommati, I., Suthanthirakumaran, M., Oh, L. C. R., Schlatter, J. N., Sarvananthan, A., Broggini, M., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1472-9 · Cited by 22
The role of cyclin D1 and Ki‐67 in the development and prognostication of thin melanoma
Kaufmann, C., Kempf, W., Mangana, J., Cheng, P. F., Emberger, M., Lang, R., Kaiser, A. K., Lattmann, E., Levesque, M. P., Dummer, R., et al. (2020) · Histopathology · doi:10.1111/his.14139 · Cited by 25
“The oncogenic effect of cyclin D1 overexpression or gene amplification is primarily attributed to its impact on tumour cell proliferation, but proliferation-independent oncogenic mechanisms have also been proposed.(12) These include effects of cyclin D1 on cellular migration and invasion, which were first described in…”
BackgroundYuan, X., Zhang, P., Yu, T., Huang, H., Zhang, L., Yang, C., Tan, T., Yang, S., Luo, X., & Luo, J. (2020) · PubMed Central · Cited by 21
Cyclin D2 overexpression drives B1a-derived MCL-like lymphoma in mice
Pieters, T., T’Sas, S., Vanhee, S., Almeida, A., Driege, Y., Roels, J., Loocke, W. V., Daneels, W., Baens, M., Marchand, A., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20202280 · Cited by 23
Saikia, S., Kolita, B., Dutta, P. P., Dutta, D. J., Neipihoi, Nath, S., Bordoloi, M., Quân, P. M., Thuy, T. T., Phương, D. L., et al. (2015) · Steroids · doi:10.1016/j.steroids.2015.06.012 · Cited by 21
Synergistic growth inhibition by sorafenib and vitamin K2 in human hepatocellular carcinoma cells
Zhang, Y., Zhang, B., Zhang, A., Zhao, Y. M., Zhao, J., Liu, J., Gao, J., Fang, D.-C., & Rao, Z. (2012) · Clinics · doi:10.6061/clinics/2012(09)18 · Cited by 21
“Cyclin D1 is a checkpoint for the G1/S transition (33).”
BackgroundClinical implications of biological markers in pancreatic ductal adenocarcinoma
Giovinazzo, F., Turri, G., Zanini, S., Butturini, G., Scarpa, A., & Bassi, C. (2012) · Surgical Oncology · doi:10.1016/j.suronc.2012.07.004 · Cited by 22
Giusti, L., Valle, Y. D., Bonotti, A., Donadio, E., Ciregia, F., Ventroni, T., Foddis, R., Giannaccini, G., Guglielmi, G., Cristaudo, A., et al. (2014) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201300052 · Cited by 21
“Worthy of attention is the presence of VIM as a node that is directly related to CCND1 and CDKN1A both mediators of activity of tumor suppressor pathways as p53 and pRb in many human malignancies [32].”
BackgroundThe PML isoform IV is a negative regulator of nuclear EGFR’s transcriptional activity in lung cancer
Kuo, H.-Y., Chen, Y., Chang, H., Jeng, J., Lin, E.-H., Pan, C., Chang, Y.-W., Wang, M., Chou, Y., Shih, H., et al. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt109 · Cited by 22
Hallas, C., Phillipp, J., Domanowsky, L., Kah, B., & Tiemann, K. (2016) · BMC Cancer · doi:10.1186/s12885-016-2707-1 · Cited by 21
“Deregulated expression of cyclin D1 is found in a large variety of malignancies and often associated with tumor progression [5].”
BackgroundPark, G. H., Sung, J. H., Song, H. M., & Jeong, J. B. (2016) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-016-1364-x · Cited by 21
Dai, B., Roife, D., Kang, Y., Gumin, J., Perez, M. V. R., Li, X., Pratt, M. F., Brekken, R. A., Fueyo-Margareto, J., Lang, F. F., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0526 · Cited by 25
“Considering that about 40% to 80% of pancreatic cancers have cyclin D1 overexpression or gene amplification (30, 31), we speculate that Delta-24-RGD could be active in a large fraction of pancreatic cancers.”
BackgroundHsin, I., Hsu, J.-C., Wu, W., Lu, H., Wu, M., & Ko, J. (2018) · Environmental Toxicology · doi:10.1002/tox.22582 · Cited by 21
“β-catenin induces the transcription of cyclin-D1 mediates cancer proliferation.(7,8) Immunomodulatory protein from Ganoderma shows multiple anti-cancer abilities.”
Xie, M., Wu, Z., Ying, S., Liu, L., Zhao, C., Yao, C., Zhang, Z., Luo, C., Wang, W., Zhao, D., et al. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00589-9 · Cited by 20
Clinical Impact of 11q13.3 Amplification on Immune Cell Infiltration and Prognosis in Breast Cancer
Zhou, R., Zhu, X., Peng, Y., Zhong, L., Peng, L., Yang, B., Meng, Y., Chen, X., & Lu, Y. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s360177 · Cited by 22
“Therefore, CCND1 is considered an oncogene, and its product may serve as a driver of cell proliferation, angiogenesis, and resistance to chemotherapy and radiotherapy.(28) It has been reported that amplification ofCCND1 alone or with PAK1 indicates a reduced recurrence-free survival of patients with ER-positive breast…”
BackgroundWang, S., Bei, Y., Tian, Q., He, J., Wang, R., Wang, Q., Sun, L., Ke, J.-Q., Xie, C., & Shen, P. (2022) · Cell Proliferation · doi:10.1111/cpr.13337 · Cited by 21
Pol, M., Gao, H., Zhang, H., George, O. J., Fox, J. M., & Jia, X. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122180 · Cited by 20
Su, Y., Meng, L., Ge, C., Liu, Y., Zhang, C., Yang, Y., Tian, W., & Tian, H. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03062-3 · Cited by 25
“Activated EGFR/ ERK signaling has been tightly linked to the expression of cyclin D1 [25].”
BackgroundYang, C., Lu, R., Lin, C., Jen, C.-H., Tung, C.-Y., Yang, S., Lin, J.-K., Jiang, J.-K., & Lin, C.-H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100060 · Cited by 21
Lentivirus-mediated knockdown of Krüppel-like factor 9 inhibits the growth of ovarian cancer
Zhang, Q., Dou, H.-T., Tang, Y., Su, S., & Liu, P. (2014) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-014-3405-3 · Cited by 22
“regulator of cell proliferation and its expression is subject to both transcriptional and post-transcriptional regulation [13, 14].”
Zhu, H., Ma, J., Song, X., Gao, H., Ma, C., Chang, H., Li, H.-G., Liu, F., Lu, J., & Zhou, X. (2016) · Oncology Reports · doi:10.3892/or.2016.5187 · Cited by 20
DDA 1, a novel oncogene, promotes lung cancer progression through regulation of cell cycle
Cheng, L., Yang, Q., Li, C., Dai, L., Yang, Y., Wang, Q., Ding, Y., Zhang, J., Liu, L., Zhang, S., et al. (2017) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13084 · Cited by 21
Lee, S. J., Lee, J. S., Lee, E., Lim, T., & Byun, S. (2018) · Journal of Functional Foods · doi:10.1016/j.jff.2018.04.050 · Cited by 21
Sensitization of prostate cancer to radiation therapy: Molecules and pathways to target
Mu, Y., Rogers, L. J., Suchowerska, N., Choe, D. J., Al‐Dabbas, M. A., Narula, R. S., Lyons, J. G., Sved, P. D., Zhong, L., & Dong, Q. (2018) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2018.05.021 · Cited by 21
Wang, S., Huang, L., Zhang, Y., Peng, Y., Wang, X., & Peng, Y. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.10.003 · Cited by 20
Gündoğdu, G., Dodurga, Y., Elmas, L., Tascı, S. Y., & Karaoğlan, E. S. (2018) · Eurasian Journal of Medicine · doi:10.5152/eurasianjmed.2018.17403 · Cited by 20
Prognostic value of cyclin A2 and B1 expression in lung carcinoids
Brčić, L., Heidinger, M., Sever, A. Z., Zacharias, M., Jakopović, M., Fediuk, M., Maier, A., Quehenberger, F., Seiwerth, S., & Popper, H. (2019) · Pathology · doi:10.1016/j.pathol.2019.03.011 · Cited by 20
Obesity/Type 2 Diabetes-Associated Liver Tumors Are Sensitive to Cyclin D1 Deficiency
Luo, C., Liang, J., Sharabi, K., Hatting, M., Perry, E. A., Tavares, C. D. J., Goyal, L., Srivastava, A., Bilodeau, M., Zhu, A. X., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0106 · Cited by 21
Li, H., Li, Q., Li, Y., Sang, X., Yuan, H., & Zheng, B. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00768 · Cited by 20
“Some studies have found that CCND1 can regulate the cell cycle by controlling the G1/S phase transition, and increased expression of CCND1 will lead to the occurrence of cancer (Musgrove et al., 2011).”
BackgroundLee, L. K., & Foo, K. Y. (2013) · Food Research International · doi:10.1016/j.foodres.2013.03.027 · Cited by 23
Su, H., Jin, X., Shen, L., Fang, Y., Fei, Z., Zhang, X., Xie, C., & Chen, X.-L. (2015) · Tumor Biology · doi:10.1007/s13277-015-4393-z · Cited by 20
“Cyclin D1 gene (CCND1) encodes a regulatory subunit of the cyclin-dependent kinase 4 (CDK4) and CDK6, whose activity is required for cell cycle G1/S transition [13].”
BackgroundMicroRNA Signaling Pathway Network in Pancreatic Ductal Adenocarcinoma
Sun, L., Chua, C. Y. X., Tian, W., Zhang, Z., Chiao, P. J., & Zhang, W. (2015) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2015.07.003 · Cited by 20
Matikas, A., Foukakis, T., & Bergh, J. C. S. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.04.002 · Cited by 19
CENPO regulated proliferation and apoptosis of colorectal cancer in a p53-dependent manner
Liu, Z., Chen, C., Yan, M., Zeng, X., Zhang, Y., & Lai, D. (2022) · Discover Oncology · doi:10.1007/s12672-022-00469-2 · Cited by 20
“poor clinical prognosis and distant metastasis of CRC patients, which are considered as the poor prognosis indicator of CRC [40, 41].”
BackgroundNguyen, N. T., Chaudhry, S., Totiger, T. M., Diaz, R., Roberts, E. R., Montoya, S., Pardo, G., Pardo, A., Afaghani, J., Affer, M., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00315-2 · Cited by 20
Coming of Age: Targeting Cyclin K in Cancers
Xiao, Y., & Dong, J. (2023) · Cells · doi:10.3390/cells12162044 · Cited by 20
“Given the critical role of cyclins/CDKs in cancer, cyclin/CDK-targeting therapies have been the focal point of cancer research for many years [12,15,16].”
Snail Expression Is Associated With a Poor Prognosis in Malignant Pleural Mesotheliomas
Kobayashi, M., Huang, C., Sonobe, M., Kikuchi, R., Ishikawa, M., Imamura, N., Kitamura, J., Iwakiri, S., Itoi, K., Yasumizu, R., et al. (2013) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2013.01.012 · Cited by 19
Yao, H., Feng, L., Zhou, J., Zhang, R., & Wang, M. (2016) · PubMed Central · Cited by 19
Chen, Y., Zhang, Z., Henson, E. S., Cuddihy, A. R., Haigh, K., Wang, R., Haigh, J. J., & Gibson, S. B. (2021) · Autophagy · doi:10.1080/15548627.2021.1973338 · Cited by 19
Cyclin D1 expression in peripheral T-cell lymphomas
Song, J. Y., Song, L., Herrera, A. F., Venkataraman, G., Murata‐Collins, J. L., Bedell, V., Chen, Y. Y., Kim, Y. S., Tadros, R., Nathwani, B. N., et al. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.136 · Cited by 20
Lee, H.-C., Liang, A., Lin, Y., Guo, Y., & Huang, S. (2017) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2017.03.003 · Cited by 19
The role of abemaciclib in treatment of advanced breast cancer
McCartney, A., Moretti, E., Sanna, G., Pestrin, M., Risi, E., Malorni, L., Biganzoli, L., & Leo, A. D. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918776925 · Cited by 21
Metadata
- Authors
- Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L.
- Affiliations
- Garvan Institute of Medical Research (AU)
- Corresponding author
- Sutherland, Robert L.
- ORCID
- Caldon, C. Elizabeth
- Venue
- Nature Reviews Cancer
- Published
- 2011-07-07
- Volume
- 11
- Issue
- 8
- Pages
- 558-572
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2089655089
- Cited by
- 1,370
- References
- 190
- Citations by year
- 2026: 54 · 2025: 65 · 2024: 57 · 2023: 78 · 2022: 85 · 2021: 102 · 2020: 113 · 2019: 100 · 2018: 93 · 2017: 130 · 2016: 129 · 2015: 105 · 2014: 92 · 2013: 91 · 2012: 75
- FWCI
- 7.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Keywords
- cyclin D1, cyclin D, cyclin-dependent kinases, CDK4, CDK6, oncogene deregulation, cancer therapy, therapeutic target, biomarkers, patient subgroup identification, tumor progression
- MeSH terms
- Humans, Neoplasms, Oncogenes, Polymorphism, Genetic, Cyclin D
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.